Moneycontrol PRO
Upcoming Webinar:Moneycontrol Pro in association with Quants League Sep'21 Edition brings to you to 5-Days Live Algorithmic Options Trading Virtual Conference. Register Now!

Marksans Pharma rallies 5% after Goa unit receives EIR from USFDA

The facility was inspected by the US Food and Drug Administration between February 25 and March 6

June 06, 2019 / 04:01 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Marksans Pharma rallied five percent to close at Rs 22.95 on June 6 after receiving an Establishment Inspection Report (EIR) for its Goa facility. The facility was inspected by the US Food and Drug Administration between February 25 and March 6.

"We received an Establishment Inspection Report (EIR) from the USFDA in respect of inspection of the company's Goa facility," it said in an exchange filing.

Mumbai-based Marksans is engaged in research, manufacturing and marketing of generic pharmaceutical formulation in global markets.

The company's robust product portfolio is spread over major therapeutic segments of CVS, CNS, anti-diabetic, pain management, gastroenterologicals and anti-allergies.
Moneycontrol News
first published: Jun 6, 2019 04:01 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark